Verrica Pharmaceuticals Inc. Cost of Revenue
Verrica Pharmaceuticals Inc. (VRCA) reported Cost of Revenue of $700.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2025-05-13
- Verrica Pharmaceuticals Inc. cost of revenue for the quarter ending 2025-03-31 was $700.00K, a 0.00% change year-over-year.
- Verrica Pharmaceuticals Inc. cost of revenue for the quarter ending 2024-12-31 was $800.00K, a 300.00% increase year-over-year.
- Verrica Pharmaceuticals Inc. cost of revenue for the quarter ending 2024-09-30 was $400.00K, a 33.33% increase year-over-year.
- Verrica Pharmaceuticals Inc. cost of revenue for the quarter ending 2024-06-30 was $700.00K.
- Verrica Pharmaceuticals Inc. cost of revenue for fiscal 2024 was $2.60M, a 420.00% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. cost of revenue for fiscal 2023 was $500.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-03-31 | $700.00K 10-Q · filed 2025-05-13 | $1.50M derived: sum of 2 quarters · filed 2025-05-13 | $1.90M derived: sum of 3 quarters · filed 2025-05-13 | $2.60M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.20M derived: sum of 2 quarters · filed 2025-03-11 | $1.90M derived: sum of 3 quarters · filed 2025-03-11 | $2.60M 10-K · filed 2025-03-11 |
| 2024-09-30 | $400.00K 10-Q · filed 2024-11-05 | $1.10M derived: sum of 2 quarters · filed 2024-11-05 | $1.80M 10-Q · filed 2024-11-05 | $2.00M derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | $700.00K 10-Q · filed 2024-08-14 | $1.40M 10-Q · filed 2024-08-14 | $1.60M derived: sum of 3 quarters · filed 2025-03-11 | $1.90M derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | $700.00K 10-Q · filed 2024-05-13 | $900.00K derived: sum of 2 quarters · filed 2025-03-11 | $1.20M derived: sum of 3 quarters · filed 2025-03-11 | |
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $500.00K derived: sum of 2 quarters · filed 2025-03-11 | $500.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | $300.00K 10-Q · filed 2023-11-09 | $300.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |